Compare CCRN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCRN | VNDA |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.7M | 387.9M |
| IPO Year | 2001 | 2005 |
| Metric | CCRN | VNDA |
|---|---|---|
| Price | $13.20 | $5.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.15 | ★ $14.90 |
| AVG Volume (30 Days) | 493.1K | ★ 875.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $816,484,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $5.01 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $7.43 | $4.14 |
| 52 Week High | $14.98 | $9.91 |
| Indicator | CCRN | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 74.08 | 45.29 |
| Support Level | $13.02 | $5.67 |
| Resistance Level | $13.23 | $6.73 |
| Average True Range (ATR) | 0.03 | 0.25 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 57.14 | 52.24 |
Cross Country Healthcare Inc is a healthcare workforce solutions company delivering an AI-powered digital platform and advisory services to help health systems manage their labor ecosystem. It operates through two reportable segments: Nursing and Allied Staffing, which generates maximum revenue and provides staffing, recruiting, total talent solutions, vendor neutral programs, managed service programs, education healthcare services, caregiver services to PACE programs and outsourcing services; and Physician Staffing, which provides licensed practitioners including certified registered nurse anesthetists, nurse practitioners and physician assistants on temporary assignments. The company recruits professionals nationally and places them with healthcare facilities across the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.